Microsoft: Earnings Estimates For Q1 2022

Microsoft (NASDAQ: MSFT) will be reporting its first quarter financial results on the 26th after the markets close. Analysts have a consensus $339.26 12-month price target on the company, via a total of 41 analysts, with 17 analysts having strong buy ratings. 22 analysts meanwhile have buy ratings, and 2 analysts have hold ratings on the company. The street high sits at a $384 price target, and the lowest target sits at $281.78.

25 analysts have revenue estimates for the first quarter. The mean revenue estimate between all 25 analysts is $44.97 billion; this number has been revised upwards from $41.90 billion at the start of April. The highest revenue estimate is $44.77 billion, while the lowest is $43.66 billion.

Onto EBITDA estimates, there are currently 4 analysts who have first-quarter EBITDA estimates. The mean is currently $22.28 billion, with this number having been revised upwards from $20.35 billion at the start of April. The street high estimate currently sits at $22.76 billion in EBITDA and the lowest is $21.56 billion.

Analysts estimate that quarterly earnings per share will come in at $2.07, with this number being revised upwards from $1.90 at the start of April. Street high is $2.17 and the lowest estimate is $2.03 per share for the quarter.


Information for this briefing was found via Edgar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Gold Prices Are High, Experience Matters | Rob McLeod

Silver Is a Wild Animal, Gold Heads for $6,000 in 2026 | Craig Hemke

Is This the End of the Gold and Silver Rally? | Peter Grandich

Recommended

Emerita Drills 1.4% Copper Over 9.2 Metres At El Cura In Advance Of Prefeasibility Study

Steadright Hints At Near Term Mineral Extraction From New Copper Valley Project

Related News

Antibe: Canaccord Cuts Price Target From $5.00 To $1.20 After Drug Pivot

In early August, Antibe Therapeutics Inc. (TSX: ATE) announced that they have paused their study...

Monday, October 18, 2021, 11:31:00 AM

Microsoft Is Going Nuclear, Hiring Post Reveals

Microsoft (NASDAQ: MSFT), the tech giant headquartered in Seattle, is taking bold strides towards supplying...

Monday, September 25, 2023, 10:07:08 AM

Microsoft-Activision Merger Likely To Face FTC Hurdle

The regulatory oversight might add heat to what the US$69 billion acquisition deal already feels...

Thursday, November 24, 2022, 10:07:00 AM

Hexo: Canaccord Raises Price Target To $1.25 Following Q1 Results

Yesterday, Hexo Corp (TSX: HEXO) (NYSE: HEXO) released its fiscal first quarter 2021 financial results....

Tuesday, December 15, 2020, 11:05:36 AM

Peloton: BMO Remains As The Bear Following Q4 Results

At the tail end of August, Peloton Interactive (NASDAQ: PTON) reported its fiscal fourth quarter...

Saturday, September 4, 2021, 01:10:00 PM